Halitosis in young patients with chronic kidney disease: findings from a randomized controlled trial

Head & Face Medicine

Table 2 OralChroma™ VSC measurements at baseline, 3 and 6 months in young CKD patients

Patient ID / group	Dimethyl sulfide (ppb)			Hydrogen sulfide (ppb)			Methyl mercaptan (ppb)
Patient ID / group	Baseline	3 months	6 months	Baseline	3 months	6 months	Baseline	3 months	6 months
OPP
9 (*)	0	197	110	0	0	4	0	0	39
19	0	0	0	0	31	2	0	0	0
28	12	m.v.	m.v.	232	m.v.	m.v.	53	m.v.	m.v.
10	21	m.v.	0	14	m.v.	0	0	m.v.	0
23	21	342	0	0	0	0	0	165	18
21	40	73	0	11	43	0	0	43	5
2	48	0	21	4	46	0	0	0	0
33	48	0	0	0	23	266	0	0	204
1	49	0	36	11	4	0	5	0	10
16	49	499	28	0	138	14	0	246	0
13	61	12	0	35	10	2	0	0	0
24	64	96	0	446	19	15	95	0	0
8	69	149	83	0	0	0	0	0	0
29(*)	84	0	12	0	0	0	43	0	0
32	130	12	0	0	0	61	62	0	107
TAU
5	0	24	0	158	101	58	10	24	10
7	0	73	21	74	78	4	0	18	0
18	0	21	42	0	13	2	0	10	10
20	0	0	0	13	0	18	0	0	0
22	0	36	115	11	71	356	0	0	58
17	12	0	33	0	0	0	0	0	19
12	21	84	120	111	264	21	27	65	31
26	42	0	100	133	0	347	31	0	0
34	42	178	679	1634	3476	505	582	0	43
25	64	40	0	19	129	0	0	18	0
3	77	28	42	15	105	58	41	0	5
31	95	m.v.	303	35	m.v.	0	0	m.v.	47
11	100	m.v.	95	16	m.v.	23	5	m.v.	23
30	127	0	0	23	12	0	0	0	0
14	149	79	0	71	0	0	0	0	0

Measurements above threshold according to Tangermann and Winkel highlighted in bold * Chlorhexidine mouthwash after baseline within the TAU group; m.v. missing value

ISSN: 1746-160X